Australian startup 4DMedical Limited, the global leader in advanced respiratory imaging, has announced that CT:VQ™ technology has Therapeutic Goods Administration (TGA) approval and is included on the Australian Register of Therapeutic Goods (ARTG), enabling commercial deployment across Australia.
CT:VQ™ gives physicians access to ventilation and perfusion imaging and data derived directly from routine, non-contrast, chest CT scans. CT:VQ™ delivers regional functional lung information without the use of injected contrast agents, radiotracers, or dedicated nuclear medicine infrastructure.
"TGA approval marks an important milestone for respiratory diagnostics in our home market," said Andreas Fouras, Founder, Managing Director and CEO of 4DMedical.
Ventilation-perfusion imaging typically requires dedicated nuclear medicine equipment, radiotracers, and specialized operational workflows. But CT:VQ™ provides a software-based alternative that integrates off scans performed from existing CT imaging infrastructure—potentially expanding access to functional lung assessment across a broader range of healthcare settings.
Since receiving FDA clearance in 2025, CT:VQ™ has been deployed at leading US institutions including Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, University of Miami, and SimonMed, one of the largest private outpatient radiology networks in the United States.
